Rieche K, Wolff G
Arch Geschwulstforsch. 1975;45(5):485-8.
It can be said that a single hormone therapy with testosterone decanoate, drostanolone, and testosterone gave similar rates of objective responses in metastatic breast cancer. The presented randomized study has been done to prove whether an additional chemotherapy to hormone applications would further improve therapeutic results. During an observation period of 10 to 16 weeks testosterone decanoate and testolactone in combination with cyclophosphamide have more benefitial effects on the patients than drostanolone plus cyclophosphamide. The combination therapy augmented the rate of objective responses from 22-25 percent to 46-55 percent.
可以说，使用癸酸睾酮、羟甲雄酮和睾酮进行单一激素治疗，在转移性乳腺癌中产生的客观缓解率相似。开展这项随机研究是为了证明在激素治疗基础上增加化疗是否会进一步改善治疗效果。在10至16周的观察期内，癸酸睾酮和睾内酯联合环磷酰胺对患者的疗效优于羟甲雄酮加环磷酰胺。联合治疗使客观缓解率从22% - 25%提高到了46% - 55%。
